Citizens Reiterates Market Outperform on Abivax, Maintains $131 Price Target

Benzinga Newsdesk www.benzinga.com Negative 93.6%

Neg 93.6% Neu 0% Pos 0%

Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ:ABVX) with a Market Outperform and maintains $131 price target.